The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Biovail Corporation and Elan Corporation, PLC; Analysis to Aid Public Comment
DC Credit Services, Inc., and David Cohen., U.S. (for the FTC)
FTC Staff Comment Before Federal Energy Regulatory Commission Concerning Standardized Transmission Service and Wholesale Electric Market Design
FTC and Department of Justice Comment to the North Carolina State Bar Concerning Proposed State Bar Opinions Concerning Non-Attorney Involvement in Real Estate Transactions
Closing letter to Ms. Starr Lee, President, AGirlLikeU.com, Inc.
Commercial Alert Response Letter
Biovail Corporation
The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed the acquired license in the U.S. Food and Drug Administration’s “Orange Book” for the purpose of blocking generic competition to its branded Tiazac. The consent order requires Biovail to divest part of its exclusive rights to DOV; prohibits the firm from taking any action that would trigger additional statutory stays on final FDA approval of a generic form of Tiazac; and also prohibits Biovail from wrongfully listing any patents in the Orange Book for a product for which the company already has an New Drug Application from the FDA.
0206004 Informal Interpretation
0206003 Informal Interpretation
Prepared Statement of the Federal Trade Commission On The Franchise Rule
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
0206007 Informal Interpretation
FMC Corporation and Asahi Chemical Industry Co., Ltd
A consent order settled charges that FMC and Asahi Chemical Industry Co. Ltd. of Japan entered into a conspiracy to divide the world market for microcrystalline cellulose (MCC), a binder used in making pharmaceutical tablets, into two territories. According to the complaint, FMC allegedly agreed not to sell the pharmaceutical to customers in Japan or East Asia without Asahi Chemical's consent, while Asahi Chemical agreed not to sell the pharmaceutical to customers in North America or Europe without the consent of FMC. The final order prohibits such behavior in the future and restricts FMC from acting as the U.S. distributor for any competing manufacturer of microcrystalline cellulose (including Asahi Chemical) for 10 years. In addition, for five years, FMC is prohibited from distributing in the United States any other product manufactured by Asahi Chemical.